arrow
C

Clémentine Sarkozy

université versailles saint-quentin
H指数:33
被引数:7,707

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

End-of-induction circulating tumor DNA outperforms conventional cellular MRD for predicting early progression in follicular lymphoma: an ancillary study of the RELEVANCE randomized trial

诱导治疗结束时的循环肿瘤DNA优于常规细胞微小残留病,用于预测滤泡性淋巴瘤的早期进展:RELEVANCE随机试验的辅助研究

2026-09-290
OAAI
Contemporary Treatment and Survival Outcomes in Mantle Cell Lymphoma: A National Real-World Analysis From REALYSA, a LYSA Cohort

套细胞淋巴瘤的现代治疗与生存结局:来自REALYSA(LYSA队列)的国家真实世界分析

2026-09-220
OAAI
Beyond maximum grade: the role of real-world digital health technologies to capture, predict, and manage treatment toxicity in haematological cancers

超越最大等级:现实世界数字健康技术在血液系统癌症中捕捉、预测和管理治疗毒性的作用

2026-08-270
PRE
Large B-cell Lymphoma: The LYSA pragmatic guidelines

弥漫大B细胞淋巴瘤:LYSA实用性指南

2025-12-030
OAAI
Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy: A Descar-T Study By Lysa Group

抗CD19 CAR-T细胞疗法失败后套细胞淋巴瘤患者的结局:Descar-T研究(Lysa集团)

2025-10-030
OAAI
Efficacy of tazemetostat in combination with R-CHOP in elderly patients newly diagnosed with diffuse large B cell lymphoma: results of the EpiRCHOP phase II study of the LYSA

塔泽莫斯托stat与R-CHOP联合治疗新诊断弥漫性大B细胞淋巴瘤老年患者的疗效:LYSA的EpiRCHOP II期研究结果

2025-04-010
PRE
Aberrant Cytoplasmic Expression of p16 Is a New Strong Prognostic Marker in Young MCL Patients Treated By Frontline Cytarabine-Based Immunochemotherapy, a Study from the Lysa Group, Nordic Lymphoma Group and the European MCL Network

p16的异常细胞质表达是接受一线阿糖胞苷为基础的免疫化疗的年轻MCL患者的一个新的强预后标志物,一项来自Lysa Group、Nordic Lymphoma Group和European MCL Network的研究

BLOOD
IF23.1
2024-11-050
PRE
Outcome of Patients with Mantle Cell Lymphoma after Failure of Anti-CD19 CAR T-Cell Therapy: A Descar-T Study By Lysa Group

抗CD19 CAR T细胞疗法失败后滤泡性淋巴瘤患者的结局:Lysa Group的Descar-T研究

BLOOD
IF23.1
2024-11-050
PRE
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of TP53 mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group
2023-11-304
OAAI
The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms (vol 36, pg 1720, 2022)

世界卫生组织第5版血淋巴肿瘤分类: 淋巴肿瘤 (第36卷,1720页,2022)

LEUKEMIA
IF13.4
2023-07-1915
OAAI
Sequence analyses of relapsed or refractory diffuse large B-cell lymphomas unravel three genetic subgroups of patients and the GNA13 mutant as poor prognostic biomarker, results of LNH-EP1 study
2023-01-181
OAAI
Single-cell profiling reveals a memory B cell-like subtype of follicular lymphoma with increased transformation risk
2022-11-0914
OAAI
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms

世界卫生组织第5版血淋巴肿瘤分类: 淋巴肿瘤

LEUKEMIA
IF13.4
2022-06-221.6K
OAAI
PHASE 1 STUDY OF SEA-TGT, A HUMAN, NONFUCOSYLATED ANTI-TIGIT MONOCLONAL ANTIBODY WITH ENHANCED IMMUNE-EFFECTOR FUNCTION, IN PATIENTS WITH ADVANCED MALIGNANCIES (SGNTGT-001, TRIAL IN PROGRESS)
2021-11-101
OA